ZEFER and H2ME deliver 100 hydrogen taxis to Copenhagen and achieve a key milestone for transport in Europe
Two pan-European projects have collaborated to bring zero emission hydrogen taxis and a new hydrogen refuelling station to the Danish capital city.
The ZEFER (Zero Emission taxi Fleets for European Rollout) and H2ME2 (Hydrogen Mobility Europe) projects, both funded by Europe’s Clean Hydrogen Partnership1, have deployed 100 hydrogen taxis in Copenhagen with app-based taxi company DRIVR. The Toyota Mirais run on green hydrogen from renewable energy, following the installation and opening of a new hydrogen refuelling station (HRS) in the city.
This latest deployment of taxis means the wider ZEFER project has achieved its full complement of 180 FCEVs in high-utilisation, captive fleets across Europe with deployments in three capital cities (Paris, London and Copenhagen). The taxi deployment in Copenhagen will complement 60 taxis previously deployed to Hype by STEP in Paris, and 60 other passenger cars in London deployed between private-hire firm Green Tomato Cars (50) and the Metropolitan Police (10).
To date the 120 vehicles operated under the ZEFER project have driven over 7 million kilometres fuelled only by hydrogen. This high mileage is achieved as the project deliberately targets the very long daily mileage applications which are most suitable to hydrogen vehicles. They have achieved this without major safety or reliability incidents and vehicle performance has been rated highly by drivers and fleet managers, with limited breakdowns or issues encountered relating directly to the hydrogen drivetrain.
The Danish government have targeted all taxis to be zero emission by 2030 and DRIVR won the public tender to deliver ad-hoc taxi services in the City of Copenhagen. The 100 new hydrogen taxis will complement DRIVR's existing low emission fleet, already comprising hybrid, electric and hydrogen vehicles.
“We are incredibly proud that DRIVR has been entrusted with the important task of helping the municipality of Copenhagen reach its environmental goals, and we’re very grateful for the cooperation with Toyota, which has enabled us to meet their needs with the new Toyota Mirai hydrogen cars.” said Haydar Shaiwandi, CEO DRIVR.
“While aiming to deploy its platform in 15 new cities by 2024, Hype believes that hydrogen is one of the most relevant solutions for intensive and random mobility and that the taxi market can play a key role in accelerating the adoption of hydrogen by professionals at scale. We are glad to see DRIVR ramping up the integration of hydrogen among its solutions. This demonstrates that, thanks to the support of programmes such as ZEFER, an increasing number of players are taking the hydrogen path. Early adopters will definitely have an advantage and leverage their experience moving forward.” said Mathieu Gardies, President of Hype.
- Ends -
Notes to Editor
1 previously Fuel Cell and Hydrogen 2 Joint Undertaking (FCH2 JU)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005150/en/
Contact information
Declan Shepherd
info@zefer.eu
01509 642 500
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom